Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

BioCryst begins OPuS-2 clinical trial of BCX4161 to treat patients with Hereditary Angioedema BioCryst Pharmaceuticals has dosed the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE).
Drug Research > Drug Discovery & Development > News
iCardiac Technologies IQ-CSRC study shows potential for faster drug development The Food and Drug Administration hosted the Cardiac Safety Research Consortium (CSRC) meeting to release the results of the IQ-CSRC Study demonstrating the ability to conduct robust cardiac safety characterization several years earlier in clinical development.
Drug Research > Drug Discovery & Development > News BioLineRx, Novartis to develop and commercialize Israeli-sourced drug candidates By PBR Staff Writer
Clinical-stage biopharmaceutical company BioLineRx and Novartis Pharma have reached a multi-year strategic collaboration agreement to support the development and commercialization of Israeli-sourced drug candidates.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Novogen announces breakthrough discovery melanoma treatment
Novogen, Australian/US biotechnology company, announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.
Drug Research > Drug Discovery & Development > News
Medical Research Network Goes for Transatlantic Expansion
Medical Research Network goes for Transatlantic expansion The unique Clinical Trial Support Organisation (CTSO), Medical Research Network (MRN), which offers home trial and site nurse support, as well as bespoke recruitment and retention services, has cemented its growth in Europe and the US after hiring two more professionals on either side of the Atlantic.
Drug Research > Drug Discovery & Development > Press Releases
Quality of Steel
| By Natoli Engineering Company
Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
Drug Research > Drug Discovery & Development > White Papers
First Impressions: Tablet Shape Can Impact Patient Acceptance
| By Natoli Engineering Company
First impressions are everything. This is especially true for pharmaceutical, nutritional and confectionery tablets. Discriminating consumers may decide if they will be repeat customers based on a tablet’s appearance and their experience with it. This article discusses the limitations of the flat faced bevel edge and the benefits of a flat faced radius edge tablet design.
Drug Research > Drug Discovery & Development > White Papers
ChemoCentryx reports positive results from Phase II diabetic nephropathy trial of CCX140
ChemoCentryx, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced positive top-line 52-week data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2.
Drug Research > Drug Discovery & Development > News
Lakewood-Amedex seeks FDA approval for Phase I/IIa trial of Nu-3 for diabetic foot infections
By PBR Staff Writer
US-based biopharmaceutical firm Lakewood-Amedex has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to conduct a Phase I/IIa trial of Nu-3 as a topical antimicrobial treatment for diabetic foot infections.
Drug Research > Drug Discovery & Development > News
Sunovion reports positive results from first placebo-controlled trial of dasotraline in ADHD patients
Sunovion Pharmaceuticals (Sunovion) announced positive results from the first placebo-controlled clinical study of the company’s investigational drug dasotraline for the treatment of adult patients with attention deficit hyperactivity disorder (ADHD).
Drug Research > Drug Discovery & Development > News
Janssen, USAID to expand access to anti-multidrug-resistant tuberculosis compound
By PBR Staff Writer
Johnson & Johnson's affiliate Janssen Therapeutics has signed a Memorandum of Understanding (MOU) with the US Agency for International Development (USAID) to fight against the antibiotic-resistant bacteria threat.
Drug Research > Drug Discovery & Development > News
Bayer and DNDi to develop an innovative oral treatment for human river blindness
Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis).
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250